Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)

• Status: Terminated
• Trial end date: 2019-12-02

Summary

Study B9991011 is a multi-center, international, randomized, open label, 2 component (Phase 1b followed by Phase 3), parallel-arm study of avelumab in combination with various agents for the treatment of Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL).

• Phase: Phase 3

Details

• Lead Sponsor: Pfizer
• Collaborator: EMD Serono
• Treatments: Avelumab; Azacitidine; Bendamustine Hydrochloride; Gemcitabine; Oxaliplatin; Rituximab